B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial
Conclusion: Kupffer phase CEUS surveillance with Sonazoid is extremely useful for the early detection and confirmation of HCC using a reinjection technique. Kupffer phase CEUS with Sonazoid contrast combined with the reinjection technique is, therefore, recommended as first-line screening tool for HCC in patients with liver cirrhosis, especially those with very coarse liver parenchyma.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 6, 2019 Category: Cancer & Oncology Source Type: research

Systemic Treatment Options in Hepatocellular Carcinoma
Background: Patients with advanced hepatocellular carcinoma (HCC) typically have poor survival outcomes. Until recently, sorafenib was the only systemic therapy option available and no agents were approved after sorafenib failure. However, rapid changes are beginning to emerge in the treatment landscape of advanced HCC, with approvals of regorafenib, nivolu ­mab, lenvatinib, pembrolizumab, and cabozantinib and positive phase II/III clinical trial results with other agents.Summary: Here, we provide a comprehensive overview of the clinical trial data of systemic agents that are currently approved for advanced HCC (sorafenib...
Source: Liver Cancer - May 29, 2019 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2019;8:218 –218 (Source: Liver Cancer)
Source: Liver Cancer - May 17, 2019 Category: Cancer & Oncology Source Type: research

The APPLE Association President's Message
Liver Cancer 2019;8:219 –219 (Source: Liver Cancer)
Source: Liver Cancer - May 17, 2019 Category: Cancer & Oncology Source Type: research

Apple 2019
Liver Cancer 2019;8:220 –220 (Source: Liver Cancer)
Source: Liver Cancer - May 17, 2019 Category: Cancer & Oncology Source Type: research

Pembrolizumab for the Treatment of Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 29, 2019 Category: Cancer & Oncology Source Type: research

Liver Transplant for Patients with Hepato ­cellular Carcinoma and Child-Pugh C Liver Function Should Be Mentioned in Guidelines
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: research

Sorafenib: Experience and Better Manage ­ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis
Conclusion: When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period. While mOS did not differ for patients who progressed, it was 2-fold higher in the recent period for those who had tumor control. Improvements in the use of sorafenib seem to be associated with better outcomes limited to patients with DC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2019;8:140 –140 (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2019 Category: Cancer & Oncology Source Type: research

The APPLE Association President's Message
Liver Cancer 2019;8:141 –141 (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2019 Category: Cancer & Oncology Source Type: research

Apple 2019
Liver Cancer 2019;8:142 –142 (Source: Liver Cancer)
Source: Liver Cancer - March 14, 2019 Category: Cancer & Oncology Source Type: research

Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma
Liver Cancer 2019;8:1 –5 (Source: Liver Cancer)
Source: Liver Cancer - March 7, 2019 Category: Cancer & Oncology Source Type: research

Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 7, 2019 Category: Cancer & Oncology Source Type: research

Systemic Treatment for Advanced Hepatocellular Carcinoma
Background: Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis. First-line sorafenib has been the standard of care for a decade, but the treatment landscape is expanding. This review provides a practical overview of current and future systemic treatment options for advanced HCC and their place in clinical practice.Summary: First-line sorafenib and lenvatinib have shown to improve the survival of patients with advanced HCC. In the second line, regorafenib provides benefit for patients who previously tolerated sorafenib. Anti-PD1 antibodies, nivolumab and pembrolizumab, recently became available for ...
Source: Liver Cancer - March 7, 2019 Category: Cancer & Oncology Source Type: research

Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan
Conclusion: Tumor marker score had a useful predictive prognostic value in BCLC-B HCC treated with TACE. Especially in patients with a tumor marker score of 2 or greater, a poor therapeutic response should be expected, and appropriate judgement of TACE-refractory status is necessary.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - February 18, 2019 Category: Cancer & Oncology Source Type: research